Iovance Biotherapeutics to Present at Upcoming Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma Read more about Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
Iovance Biotherapeutics to Present at Upcoming Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates Read more about Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023 Read more about Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates Read more about Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
Iovance Biotherapeutics to Present at Upcoming Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting Read more about Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma Read more about Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting Read more about Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting